Live from the NIH registry
Studies recruiting near El Paso right now
Top 25 of 194 recruiting studies, sorted by proximity — each links to its official registry page
A Study of the Efficacy and Safety of DMX-200 in Patients With FSGS Who Are Receiving an ARB
FSGS
Phase 3
Interventional 286 participants sought
MedResearch, Inc — El Paso, Texas (7.0 mi)
· Sponsor: Dimerix Bioscience Pty Ltd
Symptoms and Functions in Patients With COPD and Chronic Bronchitis Switching From CIG to THS
COPD, Smoking
N/A
Interventional 290 participants sought
El Paso Pulmonary Association — El Paso, Texas (7.0 mi)
· Sponsor: Philip Morris Products S.A.
A Study of Tersolisib (LY4064809/STX-478) With Other Anti-Cancer Treatments in Participants With Advanced Breast Cancer With a Genetic Change (PIK3CA)
Breast Neoplasms, Neoplasm Metastasis
Phase 3
Interventional 800 participants sought
Texas Oncology - West Texas — El Paso, Texas (7.0 mi)
· Sponsor: Eli Lilly and Company
Improving Glycemic Control With Electrical Stimulation
Obesity, Overweight
N/A
Interventional 60 participants sought
University of Texas at El Paso — El Paso, Texas (7.0 mi)
· Sponsor: University of Texas, El Paso
Study to Evaluate the Pharmacokinetics (PK), Safety and Tolerability up to 6 Years of Intravenous (i.v.) Secukinumab in Pediatric Participants With Juvenile Psoriatic Arthritis (JPsA).
Juvenile Psoriatic Arthritis
Phase 1
Interventional 20 participants sought
Texas Arthritis Center — El Paso, Texas (7.0 mi)
· Sponsor: Novartis Pharmaceuticals
A Study to Learn About the Study Medicine Called PF-07248144 in Combination With Fulvestrant in People With HR-positive, HER2-negative Advanced or Metastatic Breast Cancer Who Progressed After a Prior Line of Treatment.
Breast Cancer
Phase 3
Interventional 400 participants sought
Texas Oncology-West Texas — El Paso, Texas (7.0 mi)
· Sponsor: Pfizer
AngelMed Guardian® System PMA Post Approval Study
Acute Coronary Syndrome
N/A
Observational 500 participants sought
Texan Cardiovascular Institute — El Paso, Texas (7.0 mi)
· Sponsor: Angel Medical Systems
A Study With Tovorafenib (DAY101) as a Treatment Option for Progressive, Relapsed, or Refractory Langerhans Cell Histiocytosis
Recurrent Langerhans Cell Histiocytosis, Refractory Langerhans Cell Histiocytosis
Phase 2
Interventional 48 participants sought
El Paso Children's Hospital — El Paso, Texas (7.0 mi)
· Sponsor: National Cancer Institute (NCI)
A Study to Assess the Safety and Efficacy of Oral Armour Thyroid Compared to Synthetic T4 for the Treatment of Primary Hypothyroidism in Adult Participants
Hypothyroidism
Phase 2, Phase 3
Interventional 2,800 participants sought
Academy of Diabetes, Thyroid and Endocrine /ID# 255735 — El Paso, Texas (7.0 mi)
· Sponsor: AbbVie
A Study in Participants With Active Systemic Lupus Erythematosus With Inadequate Response to Glucocorticoids and ≥2 Immunosuppressants
Systemic Lupus Erythematosus (SLE)
N/A
Observational 223 participants sought
El Paso Medical Research Institute (MedResearch, Inc) — El Paso, Texas (7.0 mi)
· Sponsor: Bristol-Myers Squibb
Pharmacokinetics, Safety, and Efficacy of Povorcitinib in Adolescent Participants With Moderate to Severe Hidradenitis Suppurativa
Hidradenitis Suppurativa (HS)
Phase 2
Interventional 40 participants sought
3A Research Llc West Location — El Paso, Texas (7.0 mi)
· Sponsor: Incyte Corporation
A Study to Compare Standard Therapy to Treat Hodgkin Lymphoma to the Use of Two Drugs, Brentuximab Vedotin and Nivolumab
Lugano Classification Limited Stage Hodgkin Lymphoma AJCC v8
Phase 3
Interventional 1,875 participants sought
El Paso Children's Hospital — El Paso, Texas (7.0 mi)
· Sponsor: National Cancer Institute (NCI)
A Study to Evaluate the Efficacy and Safety of Frexalimab, Brivekimig, or Rilzabrutinib in Participants Aged 16 to 75 Years With Primary Focal Segmental Glomerulosclerosis or Minimal Change Disease
Focal Segmental Glomerulosclerosis, Glomerulonephritis Minimal Lesion
Phase 2
Interventional 84 participants sought
El Paso Kidney Specialists- Site Number : 8400005 — El Paso, Texas (7.0 mi)
· Sponsor: Sanofi
A Study to Compare the Combination of Navlimetostat (BMS-986504) With Pembrolizumab and Chemotherapy Versus Placebo Plus Pembrolizumab and Chemotherapy in First-line Metastatic Non-small Cell Lung Cancer Participants With Homozygous MTAP Deletion
Metastatic Non-small Cell Lung Cancer With MTAP Deletion
Phase 2, Phase 3
Interventional 590 participants sought
Local Institution - 0374 — El Paso, Texas (7.0 mi)
· Sponsor: Bristol-Myers Squibb
A Phase IIb Study to Evaluate AZD8965 in Participants With IPF.
Idiopathic Pulmonary Fibrosis (IPF)
Phase 2
Interventional 359 participants sought
Research Site — El Paso, Texas (7.0 mi)
· Sponsor: AstraZeneca
A Study to Evaluate the Efficacy, Safety, and Pharmacokinetics of Obinutuzumab in Adolescents With Active Class III or IV Lupus Nephritis and the Safety and PK of Obinutuzumab in Pediatric Participants
Lupus Nephritis
Phase 2
Interventional 40 participants sought
Texas Arthritis Center — El Paso, Texas (7.0 mi)
· Sponsor: Hoffmann-La Roche
Study of Sacituzumab Govitecan-hziy and Pembrolizumab Versus Treatment of Physician's Choice in Patients With Triple Negative Breast Cancer Who Have Residual Invasive Disease After Surgery and Neoadjuvant Therapy (ASCENT-05/AFT-65 OptimICE-RD/GBG 119/NSABP B-63)
Triple Negative Breast Cancer
Phase 3
Interventional 1,514 participants sought
Texas Oncology — El Paso, Texas (7.0 mi)
· Sponsor: Gilead Sciences
An Efficacy and Safety Study of Intravenous Anifrolumab to Treat Systemic Lupus Erythematosus in Pediatric Participants
Systemic Lupus Erythematosus
Phase 3
Interventional 100 participants sought
Research Site — El Paso, Texas (7.0 mi)
· Sponsor: AstraZeneca
Efficacy and Safety of a New Formulation of Oral Cladribine Compared With Placebo in Participants With Generalized Myasthenia Gravis (MyClad)
Generalized Myasthenia Gravis
Phase 3
Interventional 264 participants sought
ANESC Research — El Paso, Texas (7.0 mi)
· Sponsor: Merck Healthcare KGaA, Darmstadt, Germany, an affiliate of Merck KGaA, Darmstadt, Germany
Palazestrant in Combination With Ribociclib for the First-line Treatment of ER+/HER2- Advanced Breast Cancer
Breast Cancer, Locally Advanced Breast Cancer
Phase 3
Interventional 1,000 participants sought
Clinical Trial Site — El Paso, Texas (7.0 mi)
· Sponsor: Olema Pharmaceuticals, Inc.
Study of INBRX-106 and INBRX-106 in Combination With Pembrolizumab (Keytruda®) in Subjects With Locally Advanced or Metastatic Solid Tumors (Hexavalent OX40 Agonist)
Solid Tumor, Non-Small Cell Lung Cancer
Phase 1, Phase 2
Interventional 340 participants sought
Renovatio Clinical - El Paso — El Paso, Texas (7.0 mi)
· Sponsor: Inhibrx Biosciences, Inc
A US Non-interventional, Effectiveness and Safety Study of Patients Treated With SKYTROFA
Growth Hormone Deficiency
N/A
Observational 900 participants sought
Ascendis Investigational Site — El Paso, Texas (7.0 mi)
· Sponsor: Ascendis Pharma Endocrinology Division A/S
Gastroparesis Registry 4
Gastroparesis, Gastroparesis Nondiabetic
N/A
Observational 250 participants sought
Texas Tech University Health Science Center (TTUHSC) — El Paso, Texas (7.0 mi)
· Sponsor: Johns Hopkins Bloomberg School of Public Health
Long-Term Safety and Efficacy of Plozasiran in Adults With Hypertriglyceridemia
Hypertriglyceridemia
Phase 3
Interventional 869 participants sought
Research Site 27 — El Paso, Texas (7.0 mi)
· Sponsor: Arrowhead Pharmaceuticals
A Study of the Drugs Selumetinib vs. Carboplatin and Vincristine in Patients With Low-Grade Glioma
Low Grade Astrocytoma, Low Grade Glioma
Phase 3
Interventional 170 participants sought
El Paso Children's Hospital — El Paso, Texas (7.0 mi)
· Sponsor: National Cancer Institute (NCI)